Cluster of differentiation 69 (CD69) is a type II integral membrane protein, encoded by the gene mapped to human chromosome 12p13.31. CD69 is a member of the C-type lectin family of surface receptors. The encoded protein is expressed in all bone marrow-derived cells, with the exception of erythrocytes.
The antibody FN50 recognizes CD69, an lymphocyte early activation marker.
Immunogen
anti-mju-stimulated human B lymphocyts
Application
The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 1e6 cells in a suspension. The content of a vial (1 mL) is sufficient for 100 tests.
Biochem/physiol Actions
Cluster of differentiation 69 (CD69) exerts a pro-inflammatory effect by activating leukocytes. In humans, CD69 negatively regulates immune reactivity. Knockout/ deficiency of the gene increases the risk of susceptibility to autoimmune and chronic inflammatory diseases. The encoded protein might act as a prognostic marker for bendamustine response in chronic lymphocytic leukemia (CLL) patients. CD69 facilitates natural killer (NK) cell function. In addition it also helps in activation and differentiation of a wide variety of hematopoietic cells.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in phosphate buffered saline containing 15 mM sodium azide and 0.2% high-grade protease free BSA as a stabilizing agent.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A
Oncotarget, 7, 5507-5520 (2016)
Is CD69 an effective brake to control inflammatory diseases?
Gonzalez-Amaro R
Trends in Molecular Medicine, 19, 625-632 (2013)
The activation antigen CD69
Ziegler SF
Stem Cells, 12, 456-465 (1994)
Genome-wide association study and meta-analysis finds over 40 loci affect risk of type 1 diabetes
Barrett JC
Nature Genetics, 41, 703-707 (2009)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.